A federal court in Texas has bolstered Novo Nordisk’s efforts to limit the production and sale of compounded versions of its GLP-1 drugs, Wegovy and Ozempic. Here are five notes: ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Weight-loss drugs can be life-changing for people who have struggled to lose weight, however, some people who take them experience unpleasant and concerning side effects. In 2024, roughly 5 per ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications ... got a weekly shot of semaglutide, the drug in Ozempic and Wegovy ...